OmniAb, Inc. (OABI) Cash Flow Statement

The persistent gap between net loss and operating cash flow is primarily driven by substantial non-cash stock-based compensation, which averaged $4.3M per quarter. This suggests the core operational cash burn is less severe than the net loss implies, but the company remains reliant on non-cash adjustments to partially offset its operating losses.

The recent positive FCF is a critical inflection, driven by a sharp reduction in net loss and a favorable working capital swing. However, the trajectory remains volatile, as evidenced by the -35.3% FCF margin in Q1 2026, suggesting the sustainability of this improvement is contingent on maintaining the recent revenue recovery and cost discipline.

The erratic working capital pattern, with large negative swings in several quarters, indicates potential challenges in managing receivables or inventory cycles. The recent positive swing appears to be a key factor in the Q2 2026 cash flow improvement, but investors should monitor whether this represents a sustainable efficiency gain or a one-time benefit.

The extremely low capital intensity is consistent with a biotechnology platform focused on intellectual property and licensing rather than manufacturing. This asset-light structure is a positive for long-term cash generation potential, as it allows operating cash flow to be directed toward R&D and working capital needs without significant reinvestment requirements.